Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses

被引:26
|
作者
Chow, Edwin Chiu Yuen [1 ,2 ]
Talattof, Arjang [1 ,2 ]
Tsakalozou, Eleftheria [1 ,2 ]
Fan, Jianghong [1 ,2 ]
Zhao, Liang [1 ,2 ]
Zhang, Xinyuan [1 ,2 ]
机构
[1] US FDA, Div Quantitat Methods & Modeling, Off Res & Stand, Off Gener Drugs, Silver Spring, MD 20993 USA
[2] 10903 New Hampshire Ave,Bldg 75,Room 4690, Silver Spring, MD 20993 USA
来源
AAPS JOURNAL | 2016年 / 18卷 / 06期
关键词
Biopharmaceutics Classification System (BCS); excipients; gastrointestinal transporters; oral drug absorption; PBPK modeling; BIOPHARMACEUTICS CLASSIFICATION-SYSTEM; PEPTIDE TRANSPORTER PEPT1; COMMONLY USED EXCIPIENTS; P-GLYCOPROTEIN; CREMOPHOR EL; CACO-2; CELLS; BIOAVAILABILITY; PERMEABILITY; SURFACTANTS; METABOLISM;
D O I
10.1208/s12248-016-9964-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug solubility, effective permeability, and intestinal metabolism and transport are parameters that govern intestinal bioavailability and oral absorption. However, excipients may affect the systemic bioavailability of a drug by altering these parameters. Thus, parameter sensitivity analyses using physiologically based pharmacokinetic (PBPK) models were performed to examine the potential impact of excipients on oral drug absorption of different Biopharmaceutics Classification System (BCS) class drugs. The simulation results showed that changes in solubility had minimal impact on C-max and AUC(0-t) of investigated BCS class 1 and 3 drugs. Changes in passive permeability altered C-max more than AUC(0-t) for BCS class 1 drugs but were variable and drug-specific across different BCS class 2 and 3 drugs. Depending on the drug compounds for BCS class 1 and 2 drugs, changes in intestinal metabolic activity altered C-max and AUC(0-t). Reducing or increasing influx and efflux transporter activity might likely affect C-max and AUC(0-t) of BCS class 2 and 3 drugs, but the magnitude may be drug dependent. Changes in passive permeability and/or transporter activity for BCS class 2 and 3 drugs might also have a significant impact on fraction absorbed and systemic bioavailability while changes in intestinal metabolic activity may have an impact on gut and systemic bioavailability. Overall, we demonstrate that PBPK modeling can be used routinely to examine sensitivity of bioavailability based on physiochemical and physiological factors and subsequently assess whether biowaiver requirements need consideration of excipient effects for immediate release oral solid dosage forms.
引用
收藏
页码:1500 / 1511
页数:12
相关论文
共 50 条
  • [1] Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses
    Edwin Chiu Yuen Chow
    Arjang Talattof
    Eleftheria Tsakalozou
    Jianghong Fan
    Liang Zhao
    Xinyuan Zhang
    The AAPS Journal, 2016, 18 : 1500 - 1511
  • [2] Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles
    Li, Min
    Zou, Peng
    Tyner, Katherine
    Lee, Sau
    AAPS JOURNAL, 2017, 19 (01): : 26 - 42
  • [3] Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles
    Min Li
    Peng Zou
    Katherine Tyner
    Sau Lee
    The AAPS Journal, 2017, 19 : 26 - 42
  • [4] Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development
    Shaik, Abdul Naveed
    Khan, Ansar Ali
    ADMET AND DMPK, 2019, 7 (01): : 1 - 3
  • [5] Physiologically based pharmacokinetic (PBPK) modelling of oral drug absorption in older adults-an AGePOP review
    Demeester, Cleo
    Robins, Donnia
    Edwina, Angela Elma
    Tournoy, Jos
    Augustijns, Patrick
    Ince, Ibrahim
    Lehmann, Andreas
    Vertzoni, Maria
    Schlender, Jan Frederik
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 188
  • [6] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO EVALUATE DRUG-DRUG INTERACTION (DDI) RISK OF ALECTINIB.
    Cleary, Y.
    Gertz, M.
    Morcos, P. N.
    Youdim, K.
    Fowler, S.
    Yu, L.
    Sekiguchi, N.
    Takanashi, K.
    Kaneko, A.
    Phipps, A.
    Parrott, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S40 - S40
  • [7] Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Brain Levels of Drug in Rat
    Sanchez-Dengra, Barbara
    Gonzalez-Alvarez, Isabel
    Bermejo, Marival
    Gonzalez-Alvarez, Marta
    PHARMACEUTICS, 2021, 13 (09)
  • [8] Impact of Pharmaceutical Excipients on Oral Drug Absorption: A Focus on Intestinal Drug Transporters
    Zou, Ling
    Ni, Zhanglin
    Tsakalozou, Eleftheria
    Giacomini, Kathleen M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (02) : 323 - 325
  • [9] PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF ELAGOLIX FOR PREDICTION OF DRUG-DRUG INTERACTIONS (DDIS)
    Chiney, M. S.
    Polepally, A. R.
    Nader, A. M.
    Dufek, M. B.
    Klein, C. E.
    Ng, J. W.
    Shebley, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S59 - S59
  • [10] QUANTIFICATION OF CRITICAL MECHANISMS FOR STATIN DRUG INTERACTIONS USING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING.
    Alam, K.
    Chung, S.
    Isoherranen, N.
    Huang, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S46 - S46